RxDoctor Payments Data

Michael Kohrman

Neurology with Special Qualifications in Child Neurology · Akron, OHNPI 1467529347

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (46.9%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Livanova USA, Inc. at 47.4% of the total. Reporting peaked in 2022 at $1,620 and has fallen 89.3% since, to $174 in 2025.

$5,999in general payments, 2019–2025

Across 52 payments — averaging $115.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$3K
  • Neuropace, Inc.$885
  • UCB, Inc.$775
  • Vertex$413
  • Mallinckrodt Enterprises LLC$247
  • Medtronic$178
  • plus $654 from 8 others
$106,728in research payments, 2019–2025

Across 25 payments — averaging $4269.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$78K
  • UCB Biosciences Inc.$17K
  • SK Life Science, Inc.$12K

What the payments were for

  • Consulting fees$4137%
  • Speaking & faculty fees$1,15219%
  • Travel & lodging$1,62327%
  • Food & beverage$2,81047%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,999 in reported general payments places this provider in the 70th percentile of 113 neurology with special qualifications in child neurology providers in Ohio.

See all neurology with special qualifications in child neurology providers in Ohio

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate11$20,780

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$66$20,78011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 113 neurology with special qualifications in child neurology providers in Ohio.

Other neurology with special qualifications in child neurology in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →